A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Intravenous Cocaine and Oral Gamma Vinyl-Gamma-Amino Butyric Acid (VIGABATRIN) Interaction Study
概览
- 阶段
- 1 期
- 干预措施
- Vigabatrin
- 疾病 / 适应症
- Cocaine Addiction
- 发起方
- National Institute on Drug Abuse (NIDA)
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- safety/tolerability and AE assessments including HR/BP/ECG/QTc
- 状态
- 已完成
- 最后更新
- 9年前
概览
简要总结
This is a Phase 1 safety/tolerably study to determine if there are clinically significant interactions between oral vigabatrin (gamma vinyl-gamma-amino butyric acid; VGB) concurrent with intravenous (IV) cocaine infusions.
详细描述
STUDY DESIGN: This is a randomized, double-blind, placebo-controlled, parallel group study of the effects of VGB compared to placebo control on the physiological and subjective effects of IV infusions of cocaine (cocaine experienced volunteers). Subjects will be randomized within each clinical site to one of four groups (placebo control or one of three doses of VGB twice daily).During VGB steady state dosing, subjects will receive double-blind infusions of saline and cocaine. Subjects will be asked to return for follow-up approximately 7 and 14 days after the day of clinic discharge. STUDY DURATION: The maximum duration is 56 days, including 14 inpatient days of assessments and investigational products administration, and two follow-up visits after clinic discharge. SAMPLE SIZE: Twenty-four subjects will be randomized to one of three doses of vigabatrin or placebo. POPULATION: Volunteer, cocaine-experienced, non-treatment seeking cocaine users, 18 to 45 years of age.
研究者
入排标准
入选标准
- •Be between 18 and 45 years of age, inclusive
- •Currently be a non-treatment seeking cocaine user as confirmed by a positive urine test for cocaine
- •Able to provide written informed consent
- •A negative pregnancy test within 72 hours prior to receiving the first infusion of cocaine
排除标准
- •Please contact site for more information.
研究组 & 干预措施
Vigabatrin Dose 1
干预措施: Vigabatrin
Vigabatrin Dose 2
干预措施: Vigabatrin
Vigabatrin Dose 3
干预措施: Vigabatrin
Matching placebo
干预措施: Matching placebo
结局指标
主要结局
safety/tolerability and AE assessments including HR/BP/ECG/QTc
时间窗: 56 days
次要结局
- VGB/PK during cocaine infusions and effect of VGB on cocaine craving(28 days)